VM:CC - Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors

(TheNewswire)

Calgary, Canada – TheNewswire- December 21, 2023 - Voyageur Pharmaceuticals Ltd . (TSXV:VM) ( OTC :VYYRF) ("Voyageur" or the"Corporation"), a provider of innovative medical imagingsolutions, on December 19, 2023, it issued 590,735 Deferred ShareUnits ("DSUs") to directors of the Company pursuant to itsfixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one commonshare ("Common Share") of the Company effective as of thedate that the holder ceases service as a director of the Company. TheDSUs are used to compensate directors of the Corporation for theirannual retainers and are issued quarterly using a deemed value that isequal to the weighted average share price during that quarter. TheDSUs do not have an exercise price but have a starting value equal toapproximately $.0815 per DSU, based on the weighted average shareprice for the quarter ended September 30, 2023. The DSUs are subjectto the terms of the Plan and the policies of the TSX Venture Exchange(the "Exchange").  The DSUs and any Common Shares issuedpursuant to the exercise of the DSUs are subject to a four month holdin accordance with the policies of the Exchange.

AboutVoyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium,iodine and carbon fullerene Active Pharmaceutical Ingredients (API)and high-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium, iodine andcarbon contrast imaging market, Voyageur aims to become a key playerby producing its own barium, iodine, and fullerene minerals anddrugs.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As the Corporation solidifies itspresence in the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.

Voyageur is committed to sustainability andenvironmental stewardship. The Corporation envisions a future wherecarbon neutrality is the norm, and to achieve this, it plans to buildstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, itaims to become 100% carbon neutral across all its manufacturingactivities. Voyageur's commitment to the environment sets it apart asa pioneer in the industry.

At the core of the Corporation's operations, Voyageurowns a 100% interest in a barium sulphate (barite) project, theFrances Creek property. Additionally, Voyageur holds interests in ahigh-grade iodine, lithium, and bromine brine project situated inUtah, USA, further bolstering its position in the industry. Voyageuralso owns a 100% interest in two battery mineral projects which focuson copper/zinc development.

Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the imaging contrastmedia drug market. By controlling all primary input costs, from thesourcing of raw materials to final production, it plans to ensureunmatched quality and cost efficiency. Voyageurembodies the motto of " From the Earth to the Bottle ,"highlighting its commitment to responsible sourcing and manufacturingpractices.

For Further Information:

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking”Information

This news release may contain certainforward-looking information and statements, including withoutlimitation, statements pertaining to the perceived benefits toVoyageur. All statements included herein, other than statements ofhistorical fact, are forward-looking information and such informationinvolves various risks and uncertainties, including, withoutlimitation, global market factors and supply chain issues, risksrelating to the regulation and approval of Voyageur's products, andgeneral risks relating to Voyageur's business. There can be noassurance that such information will prove to be accurate, and actualresults and future events could differ materially from thoseanticipated in such information. A description of assumptions used todevelop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR+ website at www.sedarplus.ca. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.